Literature DB >> 28894050

Compounds of psoriasis with obesity and overweight.

Agnieszka Owczarczyk-Saczonek1, Waldemar Placek1.   

Abstract

Many epidemiological studies have confirmed the relationship of obesity and psoriasis, and it is believed that obesity is an independent risk factor for its development and is associated with a worse prognosis. Furthermore, the reduction of body weight, using low-calorie diet combined with exercise, reduces the severity of psoriasis.Visceral adipose tissue is the largest endocrine organ, producing proinflammatory cytokines (TNF-α, IL-6, IL-17) and adipokines (adiponectin, omentin, chemerin). They participate in the development of dyslipidemia, insulin resistance, diabetes, and consequently of the cardiovascular diseases. Macrophages of visceral adipose tissue have a special role and they increase significantly in obesity. They are responsible for the development of inflammation in adipose tissue and produce inflammatory cytokines (TNF alpha, IL-6, Il-8, Il-17, Il-18, MCP-1) and other adipokines: resistin, visfatin, retinol-binding protein 4. This explains the concept of «psoriatic march «and observations of the frequent coexistence of psoriasis with obesity. Inflammation associated with systemic disease, fanned by pro-inflammatory cytokines and adipokines produced by the visceral adipose tissue lead to the development of insulin resistance, endothelial cell damage. Endothelial dysfunction predisposes to the formation of atherosclerotic plaques and faster development of cardiovascular events. Complication of obesity is the development of non-alcoholic fatty liver disease (NAFLD), which states twice as likely in patients with plaque psoriasis and is associated with the severity of the disease. Another consequence is the development of depression. Probably the proinflammatory cytokines can interact with metabolism of neurotransmitters. Obesity also has a significant impact on the treatment of psoriasis, increasing the risk of adverse effects of systemic drugs, reducing the efficacy of biological agents which dose should be adjusted to the weight of the patient. It is a factor responsible for the increased volume of distribution and it causes low titter of drug concentration.

Entities:  

Keywords:  Obesity; Psoriasis; adipokines; adipokiny; metabolic syndrome; otyłość; zespół metaboliczny; łuszczyca

Mesh:

Substances:

Year:  2017        PMID: 28894050     DOI: 10.5604/01.3001.0010.3854

Source DB:  PubMed          Journal:  Postepy Hig Med Dosw (Online)        ISSN: 0032-5449            Impact factor:   0.270


  7 in total

1.  Bardet-Biedl Syndrome ciliopathy is linked to altered hematopoiesis and dysregulated self-tolerance.

Authors:  Oksana Tsyklauri; Veronika Niederlova; Elizabeth Forsythe; Avishek Prasai; Ales Drobek; Petr Kasparek; Kathryn Sparks; Zdenek Trachtulec; Jan Prochazka; Radislav Sedlacek; Philip Beales; Martina Huranova; Ondrej Stepanek
Journal:  EMBO Rep       Date:  2021-01-11       Impact factor: 8.807

2.  Serum sphingolipid level in psoriatic patients with obesity.

Authors:  Dorota Kozłowska; Ewa Harasim-Symbor; Hanna Myśliwiec; Anna J Milewska; Adrian Chabowski; Iwona Flisiak
Journal:  Postepy Dermatol Alergol       Date:  2019-12-30       Impact factor: 1.837

3.  Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice.

Authors:  Yi-Teng Hung; Yu-Jr Lin; Hsien-Yi Chiu; Yu-Huei Huang
Journal:  Ther Adv Chronic Dis       Date:  2021-09-29       Impact factor: 5.091

4.  Effects of scoparone on non-alcoholic fatty liver disease revealed by RNA sequencing.

Authors:  Xiaoyan Huang; Ya Gao; Houkang Cao; Jun Li; Siyi Mo; Ting Li; Jianzhao Wu; Kai Guo; Riming Wei; Kefeng Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-09       Impact factor: 6.055

5.  Impact of Inflammatory Immune Dysfunction in Psoriasis Patients at Risk for COVID-19.

Authors:  Tatiana Mina Yendo; Maria Notomi Sato; Anna Cláudia Calvielli Castelo Branco; Anna Julia Pietrobon; Franciane Mouradian Emidio Teixeira; Yasmim Álefe Leuzzi Ramos; Ricardo Wesley Alberca; Cesar Giudice Valêncio; Vivian Nunes Arruda; Ricardo Romiti; Marcelo Arnone; André Luis da Silva Hirayama; Alberto Jose da Silva Duarte; Valeria Aoki; Raquel Leao Orfali
Journal:  Vaccines (Basel)       Date:  2021-05-10

Review 6.  The Association Between Psoriasis and Cardiovascular Diseases.

Authors:  Ahmed Zwain; Mohanad Aldiwani; Hussein Taqi
Journal:  Eur Cardiol       Date:  2021-05-13

Review 7.  Can Biological Drugs Diminish the Risk of Sarcopenia in Psoriatic Patients? A Systematic Review.

Authors:  Zuzanna Piętowska; Danuta Nowicka; Jacek Szepietowski
Journal:  Life (Basel)       Date:  2022-03-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.